著者

高澤 千智 藤田 真敬 小林 朝夫 大塚 康民 鳥畑 厚志 大類 伸浩 高田 邦夫 立花 正一 柏崎 利昌 別宮 愼也

出版者

航空医学実験隊

雑誌

航空医学実験隊報告 (ISSN:00232858)

巻号頁・発行日

vol.56, no.3, pp.67-77, 2016 (Released:2020-04-11)

参考文献数

45

被引用文献数

1

---

It has been issued that many accidents are caused by impaired driving or impaired flying due to side effects of medications. In 2013, US Federal Aviation Agency (FAA) warned about aircraft accidents due to side effects of medications. Japan Ministry of Internal Affairs and Communications (JMIAC) also made recommendations to Japan Ministry of Health, Labor and Welfare (JMHLW) to confirm notification about driving ban in the patient package insert. The aviators who use an impairing medication are required to wait an appropriate periods after last medications before flying. FAA defines a waiting time from last medications to flight as five times of pharmaceutical half-lives. Japan Ministry of Land, Infrastructure, Transport and Tourism (JMLIT) also defines as two times the dosing interval. The dosing interval is generally determined by pharmaceutical half-lives. Considering above situations, Japan Air Self-Defense Force, Aeromedical Laboratory (JASDF AML), recommends a waiting time from last medications to flight as five times of pharmaceutical half-lives. Newly marketed medications are monitored through post-marketing surveillance and reviewed qualification for aviators. Monitoring periods are three years or more in US Air Force, but one year in FAA, JMLIT and JASDF. We review aeromedical decision making for the safe flight with medicated aviators and related articles.

著者

高澤 千智 馬塲 めぐみ 藤田 真敬 丸山 聡 鳥畑 厚志 大類 伸浩 桑田 成雄 菊川 あずさ 小林 朝夫

出版者

航空医学実験隊

雑誌

航空医学実験隊報告 (ISSN:00232858)

巻号頁・発行日

vol.56, no.2, pp.31-41, 2016 (Released:2020-04-11)

参考文献数

43

被引用文献数

1

---

Preventing incapacitation of aviator during flight is one of major missions in aerospace medicine. To prevent incapacitation and maintain health status of pilots, airline companies and Air Forces develop manuals and guidelines for aeromedical examination or use of medications. Though guidelines for aeromedical examinations and major diseases are defined in detail, there are no detailed guidelines about medications in chronic disease or common disease. Since early 1990s, as life-style related diseases increase, Aeromedical Laboratory has received numerous inquiries and cases to be reviewed in aeromedical council. To standardize aeromedical decision making and share information, Pharmacochemistry Section, Second Division of Aeromedical Laboratory published “Working Papers for aeromedical decision on medicated aviators” in 1999. This paper include following contents about common disease and medications. (1) Notice in initial medication (2) Aeromedical decision Cases to be avoided if possible, to be evaluated for returning flying duty during medications, to be allowed flying with medications (3) Effects for psychomotor activities (4) Cases of aviation accidents (5) Cases of aeromedical council (6) Reports of side effect In 2014 issue, we classify the risk of medications for aeromedical missions. We also have a planning to distribute digital issues in the same time. Points of considerations are academic reason and application for practical operations.